High expression of plasminogen activator inhibitor-2 (PAI-2) is a predictor of improved survival in patients with pancreatic adenocarcinoma

被引:34
作者
Smith, Ross [1 ]
Xue, AiQun
Gill, Anthony
Scarlett, Christopher
Saxby, Alexander
Clarkson, Adele
Hugh, Thomas
机构
[1] Univ Sydney, Royal N Shore Hosp, Dept Surg, St Leonards, NSW 2065, Australia
[2] Univ Sydney, Royal N Shore Hosp, Dept Pathol Anat, St Leonards, NSW, Australia
关键词
D O I
10.1007/s00268-006-0289-9
中图分类号
R61 [外科手术学];
学科分类号
摘要
Objective: Recent findings suggest that the urokinase-type plasminogen activator (uPA), its receptor (uPAR), plasminogen activator inhibitor-1 (PAI-1), and -2 (PAI-2) play key roles in cancer invasion. Summary Background Data: The prognostic value of components of this system is well established in breast cancer. However, little is known of its involvement in pancreatic cancer (PC). Methods: Quantitative real-time polymerase chain reaction (Q-RT-PCR) was used on tissue-banked specimens and immunohistochemistry (IHC) on paraffin specimens was used to measure expression of uPA, uPAR, PAI-1, and PAI-2 proteins in 46 PC and 12 cystadenoma specimens. Results were related to survival using Cox's proportional hazards testing. Results: Increased expression of uPA, uPAR, and PAI-1 in PC tissue were independently associated with a higher Union Internationale Contre le Cancer [International Union Against Cancer (UICC)] tumor stage (P < 0.001) and were intercorrelated (P < 0.001). Overexpression of uPAR indicated reduced survival (P = 0.03). Conversely, PAI-2 messenger ribonucleic acid (mRNA) overexpression, which occurred in 21 of 46 tumors, negatively correlated with tumor size (P = 0.008) and survival (P < 0.007) but not with uPA, uPAR, or tumor stage. There was good agreement between PAI-2 mRNA value and IHC score (P < 0.001). Using Cox's stepwise analysis, PAI-2 mRNA value (HR = 0.24; P = 0.001) and UICC tumor stage (HR = 2.014; P = 0.001) independently predicted survival. An IHC score for PAI-2 of 3+ or 4+ also independently predicted improved survival (HR = 2.72; P = 0.025). Conclusions: The uPA/uPAR/PAI-1 system is activated in advanced pancreatic cancer and may account for the tumor's aggressive behavior, whereas PAI-2 expression appears to be independent of uPA/uPAR/PAI-1 and is associated with improved prognosis. Because of its intercorrelation with mRNA expression, PAI-2 IHC may be used as an indicator of survival.
引用
收藏
页码:493 / 503
页数:11
相关论文
共 45 条
[1]   A urokinase-activated recombinant anthrax toxin is selectively cytotoxic to many human tumor cell types [J].
Abi-Habib, Ralph J. ;
Singh, Ravibhushan ;
Liu, Shihui ;
Bugge, Thomas H. ;
Leppla, Stephen H. ;
Frankel, Arthur E. .
MOLECULAR CANCER THERAPEUTICS, 2006, 5 (10) :2556-2562
[2]   Targeted alpha therapy for cancer [J].
Allen, BJ ;
Raja, C ;
Rizvi, S ;
Li, Y ;
Tsui, W ;
Zhang, D ;
Song, E ;
Qu, CF ;
Kearsley, J ;
Graham, P ;
Thompson, J .
PHYSICS IN MEDICINE AND BIOLOGY, 2004, 49 (16) :3703-3712
[3]   UROKINASE-TYPE PLASMINOGEN-ACTIVATOR - PROENZYME, RECEPTOR, AND INHIBITORS [J].
BLASI, F ;
VASSALLI, JD ;
DANO, K .
JOURNAL OF CELL BIOLOGY, 1987, 104 (04) :801-804
[4]   High tumor tissue concentration of urokinase plasminogen activator receptor is associated with good prognosis in patients with ovarian cancer [J].
Borgfeldt, C ;
Bendahl, PO ;
Gustavsson, B ;
Långström, E ;
Fernö, W ;
Willén, R ;
Grenman, S ;
Casslén, B .
INTERNATIONAL JOURNAL OF CANCER, 2003, 107 (04) :658-665
[5]   Enhanced expression of urokinase plasminogen activator and its receptor in pancreatic carcinoma [J].
Cantero, D ;
Friess, H ;
Deflorin, J ;
Zimmermann, A ;
Brundler, MA ;
Riesle, E ;
Korc, M ;
Buchler, MW .
BRITISH JOURNAL OF CANCER, 1997, 75 (03) :388-395
[6]  
CHAMBERS SK, 1995, CANCER, V75, P1627, DOI 10.1002/1097-0142(19950401)75:7<1627::AID-CNCR2820750712>3.0.CO
[7]  
2-V
[8]   Prognostic and predictive value of the urokinase-type plasminogen activator (uPA) and its inhibitors PAI-1 and PAI-2 in operable breast cancer [J].
Cufer, T ;
Borstnar, S ;
Vrhovec, I .
INTERNATIONAL JOURNAL OF BIOLOGICAL MARKERS, 2003, 18 (02) :106-115
[9]   The urokinase plasminogen activator system: Role in malignancy [J].
Duffy, MJ .
CURRENT PHARMACEUTICAL DESIGN, 2004, 10 (01) :39-49
[10]   Invasion and metastasis in pancreatic cancer [J].
Ellenrieder, V ;
Adler, G ;
Gress, TM .
ANNALS OF ONCOLOGY, 1999, 10 :46-50